Galera Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Selling, General & Admin	5.69	11	22.84	20.21	20.95	Upgrade
Research & Development	0.35	3.15	24.12	31.01	52.42	Upgrade
Operating Expenses	6.04	14.15	46.95	51.23	73.37	Upgrade
Operating Income	-6.04	-14.15	-46.95	-51.23	-73.37	Upgrade
Interest Expense	-	-	-11.41	-11.57	-7.19	Upgrade
Interest & Investment Income	0.25	0.55	1.6	0.51	0.03	Upgrade
Currency Exchange Gain (Loss)	-	-0.01	-0	-0	-0	Upgrade
Other Non Operating Income (Expenses)	0.29	0.45	-	-	-	Upgrade
EBT Excluding Unusual Items	-5.5	-13.15	-56.77	-62.29	-80.53	Upgrade
Merger & Restructuring Charges	-	-	-2.31	-	-	Upgrade
Impairment of Goodwill	-	-0.88	-	-	-	Upgrade
Gain (Loss) on Sale of Assets	3.5	-	-	-	-	Upgrade
Asset Writedown	-	-2.26	-	-	-	Upgrade
Legal Settlements	-	0.98	-	-	-	Upgrade
Other Unusual Items	151.05	-	-	-	-	Upgrade
Pretax Income	149.05	-19.16	-59.08	-62.29	-80.53	Upgrade
Income Tax Expense	-	-0.2	-	-0.07	-	Upgrade
Net Income	149.05	-18.96	-59.08	-62.22	-80.53	Upgrade
Preferred Dividends & Other Adjustments	85.53	-0.22	-	-	-	Upgrade
Net Income to Common	63.52	-18.73	-59.08	-62.22	-80.53	Upgrade
Shares Outstanding (Basic)	99	55	45	27	26	Upgrade
Shares Outstanding (Diluted)	99	55	45	27	26	Upgrade
Shares Change (YoY)	80.30%	22.63%	64.47%	5.03%	3.70%	Upgrade
EPS (Basic)	0.64	-0.34	-1.33	-2.30	-3.12	Upgrade
EPS (Diluted)	0.64	-0.34	-1.33	-2.30	-3.12	Upgrade
Free Cash Flow	-6.05	-12.15	-44.91	-43.45	-68.24	Upgrade
Free Cash Flow Per Share	-0.06	-0.22	-1.01	-1.60	-2.65	Upgrade
EBITDA	-6.02	-14.13	-46.69	-51.11	-72.59	Upgrade
D&A For EBITDA	0.02	0.02	0.26	0.11	0.78	Upgrade
EBIT	-6.04	-14.15	-46.95	-51.23	-73.37	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.